The effect of long-term iron treatment on plasma isoprostanes in anaemic women

Stopped

You are on the General Public view
  • Source

    -
    Public Title The effect of long-term iron treatment on plasma isoprostanes in anaemic women
    Acronym ISOPFe
    Source of Record URL http://isrctn.org/ISRCTN57167465
  • Trial

    -
    Health Condition(s) or Problem Iron deficiency anaemia
    Lay Summary Sorry, not currently available
    Who can enter the trial 1. Females aged 18 to 50 years 2. Iron deficiency anaemia, defined as haemoglobin less than 12 g/dl, and mean corpuscular volume (MCV) less than 90 fl and serum ferritin less than 20 ug/l
    Who cannot enter the trial 1. Suffer from serious chronic illness 2. Body mass index above 30 3. Smoker 4. Taking prescription drugs including contraceptive medicines 5. Regularly take medicines containing aspirin or ibuprofen 6. Pregnant or breastfeeding or are planning to become pregnant in the next two months 7. Moderately/severely elevated cholesterol (more than 6.0 mmol/l), as these factors affect either iron absorption or plasma isoprostane concentration
    What will happen Subjects with iron deficiency anaemia will be recruited and will be randomly assigned to either a treatment (n = 15) or control group (n = 15). Subjects in the treatment group will receive 200 mg FeSO4 (65 mg iron) once daily for 28 days. Controls will NOT receive a placebo, but will be instructed not to change their diet/lifestyle habits over a period of 28 days. In these subjects, plasma isoprostanes and serum NTBI will be measured at the start of the start of the study, and 28 days after their allocation to the control group. All subjects will be asked to complete a seven day estimated diet diary, starting on the day after their allocation to either the treatment or control group, in order to examine the relationship between dietary antioxidant intakes and isoprostane levels in all subjects.
    Primary aim Plasma isoprostane concentration after daily iron treatment for 28 days.
    Secondary Aim The secondary outcome is serum NTBI. In addition to measuring the primary outcome (plasma isoprostanes) before and once after once daily ferrous sulphate treatment for 28 days, we will also measure serum NTBI before and once after daily ferrous sulphate treatment for 28 days in all subjects.
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Stopped
    Nation England
    Location London
  • Contact

    -
    Contact for Public Queries Prof Catherine Geissler Department of Nutrition and Dietetics Kings College London Franklin Wilkins Building 150 Stamford Street London SE1 9NH United Kingdom +44 (0) 20 7848 4351 +44 (0) 20 7848 4195 catherine.geissler@kcl.ac.uk
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.